|
|
Post by spiro on Feb 8, 2015 10:20:22 GMT -5
|
|
|
|
Post by spiro on Feb 8, 2015 10:42:02 GMT -5
If you type in Novolog, Humalog and Apidra , all three totaled less than $5 billion in sales last year. I would assume needle aversion is the main reason for that weakness. It's very hard to find early launch script numbers for those drugs, but I have been able to find some for Exubera. This graph is from May 2007, I believe PFE stopped selling Exhubera in October that year. It's tough to figure out, but based on the $12 billion in total sales for Exhubera, my guess would be that PFE probably had between 10,000 and 12,000 total patients attempt to use their atrocity of a product. Spiro is looking forward to the comparisons in the near future. Attachment Deleted |
|
|
|
Post by mnholdem on Feb 8, 2015 10:43:42 GMT -5
Here is the la-la-la statement:
"Just as we saw with Pfizer’s first attempts at inhaled insulin Exubera,, I fear the commercial realities are that most patients will deem use of the drug as just too much trouble for a very little benefit in return."
The author is partially referring to the spirometer lung function testing, but "too much trouble"?
1. Snap in cartridge 2. Raise to lips 3. Inhale
It seems to me the most trouble with using Afrezza will be deciding which dessert to order after dinner.
|
|
|
|
Post by savzak on Feb 8, 2015 10:54:41 GMT -5
If you type in Novolog, Humalog and Apidra , all three totaled less than $5 billion in sales last year. I would assume needle aversion is the main reason for that weakness. It's very hard to find early launch script numbers for those drugs, but I have been able to find some for Exubera. This graph is from May 2007, I believe PFE stopped selling Exhubera in October that year. It's tough to figure out, but based on the $12 billion in total sales for Exhubera, my guess would be that PFE probably had between 10,000 and 12,000 total patients attempt to use their atrocity of a product. Spiro is looking forward to the comparisons in the near future. View Attachment Kevin posted this on Yahoo: kevinmik • 20 hours ago Flag 18users liked this postsusers disliked this posts2Reply Byetta - Victoza - Januvia - Launch Comparison Byetta Approval date April 29 2005 & In Pharmacies June 1 2005 Trx Nrx Rrx 3-Jun-05 271 10-Jun-05 1,086 17-Jun-05 1,240 24-Jun-05 1,558 1-Jul-05 2,229 8-Jul-05 2,298 2,219 79 15-Jul-05 3,386 3,258 128 Victoza Approval date Jan 25, 2010 Trx Nrx Rrx 29-Jan-10 5-Feb-10 12-Feb-10 49 49 19-Feb-10 411 411 26-Feb-10 1,057 1,057 5-Mar-10 1,465 1,461 4 12-Mar-10 2,164 2,147 17 Januvia Approval date Oct 17, 2006 Trx Nrx Rrx 20-Oct-06 27-Oct-06 3-Nov-06 3,602 3,595 7 10-Nov-06 5,453 5,421 32 17-Nov-06 7,231 7,169 62 24-Nov-06 6,765 6,613 152 1-Dec-06 10,771 9,611 1,160 Afrezza Approval date June 27, 2014 & In Pharmacies February 2, 2015 Less |
|
